Inclusion Criteria:

- Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and
currently event-free at the time of the evaluation.

- Performance status of 0-2 based of SWOG criteria

- Previously documented platelet count > 75,000/ul within a 35 days prior to enrollment

- Previously documented peripheral absolute neutrophil count >1,000/ul within 35 days
prior to enrollment.

- Adequate renal function

- Signed informed consent

- Female subject is post-menopausal or willing to use acceptable birth control

- Male subjects agree to use acceptable method of contraceptive

Exclusion Criteria:

- Hypersensitivity to Bortezomib, boron, or mannitol

- Female subject is pregnant or breastfeeding

- Experienced myocardial infraction within 6 months prior to enrollment

- Received other investigational new drugs within 14 days before enrollment

- Received any anti-myeloma therapy within 14 days

- Serious medical or psychiatric illness likely to interfere with participation in this
clinical study

- Diagnosed or treated for another malignancy within 3 years of enrollment